| Source: |
| Type: |
| Lipid peroxidation is a chain reaction process in which free radicals (often reactive oxygen species, or ROS) attack lipids containing carbon-carbon double bonds, especially polyunsaturated fatty acids. This attack results in the formation of lipid radicals, peroxides, and subsequent breakdown products. Lipid peroxidation can cause damage to cell membranes, leading to increased permeability and disruption of cellular functions. This damage can initiate a cascade of events that may contribute to carcinogenesis. The byproducts of lipid peroxidation, such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), can form adducts with DNA, leading to mutations. These mutations can disrupt normal cellular processes and contribute to the development of cancer. Lipid peroxidation damages cell membranes, disrupts cellular functions, and can trigger inflammatory responses. It is a marker of oxidative stress and is implicated in many chronic diseases. Negative Prognostic Indicator: In many cancers, high levels of lipid phosphates, particularly S1P, are associated with poor prognosis, indicating a more aggressive tumor phenotype and potential resistance to therapy. Mixed Evidence: The prognostic significance of lipid phosphates can vary by cancer type, with some studies showing that their expression may not always correlate with adverse outcomes. |
| 4443- | SeNPs, | Bioogenic selenium and its hepatoprotective activity |
| - | in-vivo, | LiverDam, | NA |
| 4446- | SeNPs, | Antioxidant and Hepatoprotective Effects of Moringa oleifera-mediated Selenium Nanoparticles in Diabetic Rats. |
| - | in-vivo, | Diabetic, | NA |
| 1483- | SFN, | Targeting p62 by sulforaphane promotes autolysosomal degradation of SLC7A11, inducing ferroptosis for osteosarcoma treatment |
| - | in-vitro, | OS, | 143B | - | in-vitro, | Nor, | HEK293 | - | in-vivo, | OS, | NA |
| 3946- | Shank, | Phytochemical Profile, Pharmacological Attributes and Medicinal Properties of Convolvulus prostratus – A Cognitive Enhancer Herb for the Management of Neurodegenerative Etiologies |
| - | Review, | AD, | NA |
| 3331- | SIL, | The clinical anti-inflammatory effects and underlying mechanisms of silymarin |
| - | Review, | NA, | NA |
| 3319- | SIL, | Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 3315- | SIL, | Silymarin alleviates docetaxel-induced central and peripheral neurotoxicity by reducing oxidative stress, inflammation and apoptosis in rats |
| - | in-vivo, | Nor, | NA |
| 3314- | SIL, | Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases—A comprehensive narrative review |
| - | Review, | NA, | NA |
| 3655- | SIL, | Protective effect of silymarin on oxidative stress in rat brain |
| - | in-vivo, | AD, | NA |
| 3649- | SIL, | Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis |
| 3648- | SIL, | Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years |
| - | Review, | NA, | NA |
| 3300- | SIL, | Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy |
| - | Review, | Var, | NA |
| 3295- | SIL, | Hepatoprotective effect of silymarin |
| - | Review, | NA, | NA |
| 3290- | SIL, | A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents |
| - | Analysis, | Var, | NA |
| 3289- | SIL, | Silymarin: a promising modulator of apoptosis and survival signaling in cancer |
| - | Review, | Var, | NA |
| 3288- | SIL, | Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations |
| - | Review, | Var, | NA |
| 2201- | SK, | Shikonin promotes ferroptosis in HaCaT cells through Nrf2 and alleviates imiquimod-induced psoriasis in mice |
| - | in-vitro, | PSA, | HaCaT | - | in-vivo, | NA, | NA |
| 2199- | SK, | Induction of Ferroptosis by Shikonin in Gastric Cancer via the DLEU1/mTOR/GPX4 Axis |
| - | in-vitro, | GC, | NA |
| 2198- | SK, | Shikonin suppresses proliferation of osteosarcoma cells by inducing ferroptosis through promoting Nrf2 ubiquitination and inhibiting the xCT/GPX4 regulatory axis |
| - | in-vitro, | OS, | MG63 | - | in-vitro, | OS, | 143B |
| 2227- | SK, | Shikonin induces mitochondria-mediated apoptosis and enhances chemotherapeutic sensitivity of gastric cancer through reactive oxygen species |
| - | in-vitro, | GC, | BGC-823 | - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | Nor, | GES-1 |
| 2202- | SK, | Enhancing Tumor Therapy of Fe(III)-Shikonin Supramolecular Nanomedicine via Triple Ferroptosis Amplification |
| - | in-vitro, | Var, | NA |
| 1284- | SK, | Shikonin induces ferroptosis in multiple myeloma via GOT1-mediated ferritinophagy |
| - | in-vitro, | Melanoma, | RPMI-8226 | - | in-vitro, | Melanoma, | U266 |
| 4892- | Sper, | erastin, | Spermidine inactivates proteasome activity and enhances ferroptosis in prostate cancer |
| - | in-vitro, | Pca, | PC3 | - | in-vivo, | Pca, | NA |
| 4718- | SSE, | High-Dose Selenium Induces Ferroptotic Cell Death in Ovarian Cancer |
| - | in-vitro, | Ovarian, | NA |
| 5091- | SSE, | Superoxide-mediated ferroptosis in human cancer cells induced by sodium selenite |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | Nor, | SVGp12 |
| 5088- | SSE, | Superoxide-mediated ferroptosis in human cancer cells induced by sodium selenite |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | GBM, | A172 |
| 4610- | SSE, | Rad, | Protection during radiotherapy: selenium |
| - | Review, | Var, | NA |
| 3960- | Taur, | Versatile Triad Alliance: Bile Acid, Taurine and Microbiota |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3400- | TQ, | Chemo, | Thymoquinone Ameliorates Carfilzomib-Induced Renal Impairment by Modulating Oxidative Stress Markers, Inflammatory/Apoptotic Mediators, and Augmenting Nrf2 in Rats |
| - | in-vitro, | Nor, | NA |
| 3398- | TQ, | 5-FU, | Impact of thymoquinone on the Nrf2/HO-1 and MAPK/NF-κB axis in mitigating 5-fluorouracil-induced acute kidney injury in vivo |
| - | in-vivo, | Nor, | NA |
| 3432- | TQ, | Thymoquinone: Review of Its Potential in the Treatment of Neurological Diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3559- | TQ, | Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer’s disease |
| - | Review, | AD, | NA | - | Review, | Var, | NA |
| 3571- | TQ, | The Role of Thymoquinone in Inflammatory Response in Chronic Diseases |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA |
| 2124- | TQ, | Thymoquinone: an emerging natural drug with a wide range of medical applications |
| - | Review, | Var, | NA |
| 2114- | TQ, | Anti-Aging Effect of Nigella Sativa Fixed Oil on D-Galactose-Induced Aging in Mice |
| - | in-vivo, | Nor, | NA |
| 2113- | TQ, | Potential role of Nigella sativa (NS) in abating oxidative stress-induced toxicity in rats: a possible protection mechanism |
| - | in-vivo, | Nor, | NA |
| 2132- | TQ, | Thymoquinone treatment modulates the Nrf2/HO-1 signaling pathway and abrogates the inflammatory response in an animal model of lung fibrosis |
| - | in-vivo, | Nor, | NA |
| 2136- | TQ, | Nigella sativa and thymoquinone suppress cyclooxygenase-2 and oxidative stress in pancreatic tissue of streptozotocin-induced diabetic rats |
| - | in-vivo, | Nor, | NA |
| 2086- | TQ, | Cardioprotective effects of Nigella sativa oil on cyclosporine A-induced cardiotoxicity in rats |
| - | in-vivo, | Nor, | NA |
| 2088- | TQ, | Nigella sativa L. and Its Bioactive Constituents as Hepatoprotectant: A Review |
| - | Review, | Nor, | NA |
| 2106- | TQ, | Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy |
| - | Review, | Var, | NA |
| 2110- | TQ, | Nigella sativa seed oil suppresses cell proliferation and induces ROS dependent mitochondrial apoptosis through p53 pathway in hepatocellular carcinoma cells |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HEK293 |
| 4869- | Uro, | Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 4874- | Uro, | EGCG, | A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 4876- | Uro, | Urolithin A in Health and Diseases: Prospects for Parkinson’s Disease Management |
| - | Review, | Park, | NA | - | Review, | AD, | NA |
| 4880- | Uro, | Urolithins: A Prospective Alternative against Brain Aging |
| - | Review, | AD, | NA |
| 4833- | Uro, | Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | IBD, | NA |
| 4858- | Uro, | The Metabolite Urolithin-A Ameliorates Oxidative Stress in Neuro-2a Cells, Becoming a Potential Neuroprotective Agent |
| - | in-vitro, | Nor, | NA |
| 4328- | VitB5, | Pantethine |
| - | Review, | AD, | NA |
| 635- | VitC, | VitK3, | The combination of ascorbate and menadione causes cancer cell death by oxidative stress and replicative stress |
| - | in-vitro, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:453 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid